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Abstract
Purpose While the use of quality of life (QoL) assessment
has been increasing in clinical oncology, few studies have
examined its prognostic significance in prostate cancer. We
investigated the association between QoL at presentation
and survival in prostate cancer.
Methods We retrospectively reviewed 673 patients treated
at two single-system cancer centers between January 2001
and December 2008. QoL was evaluated using EORTC-
QLQ-C30. Patient survival was defined as the time interval
between the date of first patient visit and the date of death/
date of last contact. Univariate and multivariate Cox
regression was performed to evaluate the prognostic
significance of QoL.
Results Mean age at presentation was 63.2 years. Patient
stage of disease at diagnosis was I, 4; II, 464; III, 76; IV,
107; and 22 indeterminate. Median overall survival was
89.1 months (95% CI: 46.1–132.0). QoL scales predic-
tive of survival upon univariate analysis were physical,
role, emotional, social, fatigue, nausea/vomiting, pain,
dyspnea, insomnia, loss of appetite, and constipation (p<
0.01 for all). Multivariate analyses found fatigue (p=0.02)
and constipation (p=0.01) to be significantly associated
with survival.
Conclusions Baseline QoL provides useful prognostic
information in prostate cancer. These findings have impor-
tant implications for patient stratification in clinical trials
and may aid decision making in clinical practice.
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Introduction
Prostate cancer is the most common cancer in men in North
America [1–5]. It is also the second leading cause of cancer
death among US men after lung cancer [6]. Each year in the
USA, approximately 220,000 new cases of prostate cancer
are diagnosed, and 30,000 men die of the disease [7]. Despite
its high morbidity, the etiology of prostate cancer remains
largely unknown [6]. Tumor stage and Gleason score remain
the two most powerful prognostic factors in prostate cancer
[8]. More recently, quality of life (QoL) has been suggested
to be a prognostic indicator in prostate cancer; however, there
are only a few published studies reporting upon this
association in the medical and scientific literature [9–12].
QoL is a multidimensional construct. A growing
consensus among health care providers and researchers is
that treatment efficacy should be judged by effects on both
quantity and QoL; this has led to the inclusion of QoL
assessment as a primary endpoint in cancer clinical trials
along with traditional endpoints of tumor response and
survival. Most studies measuring QoL in cancer patients
compare the effects of different treatments or assess the
effect of a single treatment longitudinally. There is general
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that patients are the best source of information regarding
their QoL. Consequently, the use of self-reported QoL
assessment has become a valuable tool for both clinical
practice and research. There are extensive data in the
literature showing that QoL tools measuring the activities of
daily life can predict survival in several different types of
cancers independent of the extent of the disease and other
clinical prognostic factors [9, 13–30]. These studies have
used different combinations of clinical and QoL factors in
multivariate models evaluating the prognostic significance
on clinical outcomes.
Although there are few studies which demonstrate the
relationshipbetweenQoLandsurvivalinpatientswithprostate
cancer [9–12], there is no “gold standard” QoL questionnaire
available. Rather, the selection of a QoL questionnaire for any
particular study is governed by the research goals of the
study. The most commonly used instrument for evaluating the
QoL of cancer patients is the European Organization for the
Research and Treatment of Cancer Core Quality of Life
Questionnaire (QLQ-C30), which emphasizes a patient's
capacity to function well [31–33]. In the current study, we
have employed the QLQ-C30 to investigate its efficacy in
predicting survival in prostate cancer patients treated with an
integrative model of care combining surgery, radiation,
hormonal, and chemotherapy as appropriate, plus comple-
mentary therapy consisting primarily of nutritional, psycho-
social, and spiritual support, naturopathic supplements, pain
management, and physical therapy/rehabilitation.
Materials and methods
Study sample
We retrospectively examined 673 histologically confirmed
prostatecancerpatientstreatedatCancerTreatmentCentersof
America® at Midwestern (MRMC) and Southwestern
(SRMC) Regional Medical Centers between January 2001
and December 2008. None of these patients had received any
treatment at our hospitals when contacted to participate in this
investigation. The inclusion criteria for participation in this
study were a histological diagnosis of prostate cancer and the
ability to read English. Patients with all stages of prostate
cancer were eligible for the study. Patients were excluded if
they were unable to give informed consent or were unable to
understand or cooperate with study conditions.
A trained clinical coordinator was responsible for
determining eligibility, describing the study, and obtaining
written informed consent. Participation in this study was
voluntary and all patients were assured that refusal to
participate would not affect their future care in any way.
Patients were not incentivized to participate in the study.
Patients who chose to participate were presented with the
questionnaire at their initial visit and instructed to return
their completed questionnaires to the clinical coordinator
within 24 h; thus, patients completed questionnaires prior to
receiving therapy at our facility.
Additional patient data recorded for this study was age at
presentation (current age), stage of disease at diagnosis, and
prior treatment history. The only follow-up information
required was the date of death or the date of last contact/last
known to be alive. This study was approved by the
Institutional Review Boards at MRMC and SRMC.
QoL assessment
QoL was assessed using the European Organization for the
Research and Treatment of Cancer Quality of Life
Questionnaire (QLQ-C30), which emphasizes a patient's
capacity to fulfill the activities of daily living. The QLQ-
C30 is a 30-item cancer-specific questionnaire that incor-
porates five functioning scales (physical, role, cognition,
emotional, and social), nine symptom scales (fatigue, pain,
and nausea/vomiting, dyspnea, insomnia, loss of appetite,
constipation, diarrhea, financial problems), and a global
health status/QoL scale. The raw scores are linearly trans-
formed to give standard scores in the range of 0–100 for
each of the functioning and symptom scales. Higher scores
in the global and functioning scales and lower scores in the
symptom scales indicate better QoL. A difference of 5–10
points in the scores represents a small change, 10–20 points
a moderate change, and greater than 20 points a large
clinically significant change from the patient's perspective
[34]. This instrument has been judged to be reliable and
valid as a result of extensive testing in a wide range of
clinical cancer populations [35–37].
Prespecified baseline clinical factors
Baseline clinical factors that were assessed for prognostic
significance were current age, stage of disease at
diagnosis, and prior treatment history. Stage at diagnosis
was categorized into two groups consisting of locore-
gional (stages I–III) and metastatic (stage IV) disease.
The prior treatment history variable categorized the
patients into those who have received definitive cancer
treatment elsewhere before coming to our institution and
those who were newly diagnosed at the time of
presentation to our institution.
Data analysis and statistical methods
Patient survival was the primary endpoint and defined as
the time interval between the date of first patient visit to the
hospital and the date of death from any cause or the date of
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obtained from the tumor registries of the Midwestern and
Southwestern Regional Medical Centers of Cancer Treatment
Centers of America.
The overall survival was calculated using the Kaplan–
Meier or product-limit method. Clinical and QoL variables
were also evaluated using univariate Cox regression analyses
to determine which parameters showed individual prognostic
value for survival. Multivariate Cox regression analyses were
thenperformed toevaluate the joint prognosticsignificanceof
those QoL and clinical factors that were shown to be
prognostic in univariate analyses. We used both forward
stepwise method as well as the block entry method (all
variables entered together at the same time in one block).
Forward stepwise method was used because, as is common in
QoL data, many of the individual QoL scales are highly
correlated. Stepwise regression avoids the problem of multi-
collinearity because two highly correlated attributes will
normally not both be entered in the model.
Cox regression with time-invariant covariates assumes
that the ratio of hazards for any two groups remains
constant in proportion over time. We checked this assump-
tion by first examining log-minus-log plots for the
categorical predictors and then fitting a Cox regression
with a time-varying covariate for each predictor in turn.
Each QLQ-C30 scale was treated as a continuous variable
for the purpose of Cox regression analyses. The effect of
QoL parameters on patient survival was expressed as hazard
ratios (HRs) with 95% confidence intervals. Pearson's
correlation coefficients were used to investigate the associ-
ation between different QoL variables. An effect was
considered to be statistically significant if the p value was
less than or equal to 0.05. All data were analyzed using
SPSS version 17.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
A total of 767 prostate cancer patients were invited to
participate in the study. Of those, 673 responded, resulting in
an acceptance rate of 87.7%. Table 1 describes the baseline
characteristics of our patient cohort. Mean age at presenta-
tion was 63.2 years. Patient stage of disease at diagnosis was
I, 4; II, 464; III, 76; IV, 107; and 22 indeterminate. Four
hundred thirty-two patients were newly diagnosed at our
hospital, while 241 were previously treated elsewhere. At the
time of this analysis, 77 patients had expired. Table 2
describes the means, medians, and standard deviations of
QLQ-C30 scale scores. Among the QLQ-C30 functioning
scales, emotional functioning had the lowest (worst) mean
score of 74.9, while the highest (best) mean score of 83.4
was recorded for physical functioning. Among the QLQ-C30
symptom scales, nausea/vomiting had the lowest (best) mean
score of 6.9, while the highest (worst) mean score of 28.5
was recorded for insomnia.
Table 3 describes the distribution of QoL scores by stage
of disease and prior treatment history. Mean global QoL
score was significantly higher for patients with stages I–III
disease (69.1) than stage IV disease (57.3); p<0.001. Mean
global QoL score was 71.5 and 59.4 for analytic and non-
analytic disease, respectively, p<0.001.
Univariate analysis: prognostic factors for overall survival
Median overall survival for the entire patient cohort was
89.1months(95% CI 46.1–132.0months)asdepictedinFig.1.
The median survival for analytic and non-analytic patients
was 81.4 and 45.2 months, respectively, p<0.001. The median
survival for patients with locoregional and metastatic disease
was 89.1 and 40.1 months, respectively, p<0.001.
Table 4 describes the results of univariate Cox regression
analyses for each QLQ-C30 scale as well as age, stage of
disease, and analytic status. The Cox proportional hazard
relative risks (RRs) along with their 95% confidence
intervals for every 1-U increase in all QLQ-C30 scales are
given. On univariate analysis, QoL scales predictive of
survival upon univariate analysis were physical, role,
emotional, social, fatigue, nausea/vomiting, pain, dyspnea,
insomnia, loss of appetite, and constipation (p<0.01 for
all). Age, stage of disease, and prior treatment history were
also found to be significant predictors of survival upon
univariate analysis (p<0.01 for all).
Multivariate analysis: prognostic factors for overall survival
Table 5 describes the results of multivariate Cox regression
analyses using the block entry method for those QLQ-C30
scales that were significant upon univariate analysis after
controlling for the effects of age, tumor stage, and prior
treatment history. Multivariate analyses found fatigue (p=
0.02) and constipation (p=0.01) to be significantly associ-
ated with survival independent of other QoL scales, age,
stage, and treatment history such that patients with lower
(better) fatigue and constipation scores had better survival.
Age, stage of disease, and prior treatment history were also
found to be significant predictors in the final multivariate
model (p<0.01 for all). The findings described above were
confirmed using the forward stepwise method.
Discussion
Carcinoma of the prostate continues to be a major health
problem in the USA. Newly diagnosed prostate cancers are
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symptoms with abnormal prostate-specific antigen (PSA)
level. As more and more men are being diagnosed with
prostate cancer worldwide, knowledge about the etiology
and prognosis of this disease is important. Prognostic
factors are essential not only in understanding the natural
history and the course of the disease but also to predict
possible outcomes of different treatments, or perhaps no
treatment at all. This is extremely important in a disease
such as prostate cancer, in which there is clear evidence that
a substantial number of cases discovered by PSA testing are
unlikely to ever become clinically significant [38]. In
addition to the known prognostic factors, such as tumor
stage and Gleason score, QoL has recently emerged as a
potential prognostic factor in patients with prostate cancer.
The current study was undertaken to investigate whether
patient QoL, as measured by the QLQ-C30, could predict
survival in prostate cancer.
We chose QLQ-C30 as a valid and a reliable tool to
assess patient QoL. The QLQ-C30 developers concentrated
on the patients' ability to fulfill the activities of daily life.
This emphasis is understandable because it was developed
for clinical trials investigating new drugs or novel combi-
nations of agents. Clinical practitioners and clinical inves-
tigators need to know what happens to a patient's capacity
to fulfill the activities of daily life at work and in the home.
Consequently, this instrument has an extensive physical
functioning scale and has many questions on clinical
symptoms as well. Furthermore, the QLQ-C30 social and
role functioning scales provide additional information on an
individual's physical functioning.
In this study, we found that fatigue and constipation were
predictive of survival independent of the effects of age at
presentation, stage of disease, and treatment history. Fatigue
is the most frequently reported symptom in cancer patients
[39–44]. An estimated 60–96% of cancer patients under-
going treatment experience fatigue, including 60–93% of
patients on radiotherapy, and 80–96% of patients on
chemotherapy [43, 45]. Several studies have demonstrated
the adverse impacts of fatigue on physical, emotional,
economic, and social aspects of cancer patients' lives [46–
51]. The principal finding of our current study, that fatigue
independently predicts patient survival in prostate cancer,
substantially augments its importance as a health care
measure to evaluate and address.
The association between QoL and subsequent prognosis
has been demonstrated in a few studies of patients with
prostate cancer. A study by Sullivan PW et al. in metastatic
hormone-refractory prostate cancer (HRPC) reported that
patients with better baseline health-related quality of life
(HRQL) have better predicted survival, time to disease
progression,andpainprognosisthanthosewithworseHRQL.
Change in HRQL (12 weeks) improved the predictive
accuracy for most clinical outcomes [12]. In an analysis of
data from three randomized phase III multicenter trials,
Table 2 Baseline QoL scores of 673 prostate cancer patients
QLQ-C30 scale Mean Median SD Range
Global 67.2 75.0 26.7 0–100
Physical 83.4 93.3 22.7 0–100
Role 79.8 100 30.2 0–100
Emotional 74.9 75 23.6 0–100
Cognitive 82.3 83.3 22.2 0–100
Social 79.0 100 28.7 0–100
Fatigue 27.9 22.2 26.9 0–100
Nausea/vomiting 6.9 0 16.6 0–100
Pain 24.7 16.7 30.6 0–100
Dyspnea 15.1 0 22.9 0–100
Insomnia 28.5 33.3 30.2 0–100
Appetite loss 13.5 0 25.6 0–100
Constipation 13.8 0 24.7 0–100
Diarrhea 8.5 0 18.9 0–100
Characteristic Categories Number Percent
Age at presentation (years) ￿ Mean 63.2
￿ Median 62.8
￿ Range 43.7–87.6
Tumor stage at diagnosis ￿ Stage 1 4 0.6
￿ Stage 2 464 68.9
￿ Stage 3 76 11.3
￿ Stage 4 107 15.9
￿ Indeterminate 22 3.3
Vital status ￿ Expired 77 11.4
￿ Alive 596 88.6
Treatment history ￿ Newly diagnosed (analytic) 432 64.2
￿ Previously treated (non-analytic) 241 35.8
Table 1 Baseline characteristics
of 673 prostate cancer
patients
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between pain and survival in castration-refractory prostate
cancer. The median survival times were 17.6 months (95%
CI, 16.1–19.1 months) and 10.2 months (95% CI, 8.6–
11.3 months; p<0.001) in men with low (<17) and high
(≥17) pain scores, respectively [10]. Another study found
that baseline patient satisfaction with health and physical
subscale, psychological and spiritual subscale, family sub-
scale, and overall HRQL are predictive of survival in patients
with prostate cancer. After adjusting for the effects of
treatment history and Gleason score, patient satisfaction with
health and physical subscale was found to be significantly
associated with survival (p=0.04) [11]. A pooled analysis of
data from three randomized control trials of metastatic
HRPC indicated that bone scan result (p<0.0001), hemo-
globin level (p<0.0001), performance status (p=0.0322),
insomnia (p=0.002), and appetite loss (p=0.0015) were
independent predictors of survival [9]. While the findings of
our study are similar to those reported by the above
researchers, direct comparisons between the studies is not
possible because of the differences in QoL instruments used,
study methodology, and the clinical and demographic factors
controlled for in the analyses.
Furthermore, it is important to recognize that the integra-
tive treatment model with its emphasis on aggressive
nutritional support, naturopathic therapy, and mind/body
medicine in conjunction with conventional prostate cancer
therapy which was usedtotreatthepatientsinvestigatedinthe
current study, has the potential for favorably modifying QoL
elements. Thus, it is at least conceivable that various
parameters such as global performance status and appetite
loss are less predictive of prognosis in patients treated with an
integrative approach than with conventional therapy only.
This issue warrants a great deal more investigation as it holds
the potential for demonstrating not only the value of QoL in
predicting outcome, but also the elements of QoL most
sensitive to modulation by integrative cancer treatment and
the effects of such modulation on clinical outcome.
Thus, the results of this study may have important
implications for both clinical and research practices in an
Fig. 1 Overall survival curve. Each drop in the probability curve indicates
one or more events. Vertical lines indicate censored patients, i.e., those
who reached the end of their follow-up without experiencing death
Table 3 Distribution of QoL scores by stage of disease and prior treatment history
QLQ-C30 scale Stage of disease Treatment history
Locoregional (N=544) Metastatic (N=107) P value Analytic (N=432) Non-analytic (N=241) P value
Global 69.1 57.3 <0.001 71.5 59.4 <0.001
Physical 84.7 77.3 0.002 86.9 77.0 <0.001
Role 82.4 67.6 <0.001 84.7 71.0 <0.001
Emotional 75.6 70.5 0.04 76.5 72.0 0.02
Cognitive 82.8 79.9 0.22 84.1 78.9 0.004
Social 80.9 68.1 <0.001 82.8 72.3 <0.001
Fatigue 25.5 40.2 <0.001 23.8 35.5 <0.001
Nausea/vomiting 6.0 11.8 0.001 4.8 10.6 <0.001
Pain 21.6 39.4 <0.001 19.4 34.2 <0.001
Dyspnea 14.9 14.3 0.82 13.2 18.4 0.005
Insomnia 27.5 34.6 0.03 26.6 32.0 0.03
Appetite loss 11.6 22.1 <0.001 9.0 21.4 <0.001
Constipation 12.5 20.6 0.002 10.1 20.5 <0.001
Diarrhea 8.3 8.7 0.85 7.8 9.8 0.20
Support Care Cancer (2012) 20:1267–1274 1271integrative oncologic care setting. They suggest that health
care professionals should evaluate baseline fatigue in all
patients and take this into consideration when planning
treatment. Fatigue should also be assessed regularly during
treatment and appropriate intervention taken to improve
fatigue when indicated. The utility of this approach to patient
management, based on the findings described in this study,
would be validated definitively if interventions that enhance
fatigue are shown toenhance survival. Thishypothesis should
be tested in prospective studies employing the QLQ-C30
subscales in prostate cancer populations.
Although this study presents interesting findings and
additional questions for further inquiry, several limita-
tions require acknowledgment. Our study, because of its
retrospective nature, relies on data not primarily meant
for research. As a result, we could not control for some
additional factors in our analyses that could influence survival
such as race, medical comorbidities, socioeconomic factors,
support system, exercise, and educational level. The patient
cohort was limited only to those patients who were English
speakers and therefore is not representative of the complete
spectrum of cancer patients. The largest cohort of patients had
stage II disease at presentation to our hospital, and thus, our
findings may not be applicable to all stages of prostate cancer,
an issue that needs further investigation. Moreover, this study
is not able to reveal causative relationships between any QoL
element and patient survival. Rather, QoL was found to act as
asurrogatemarkerforotherwiseundetectedprognosticfactors
Variable HR 95% CI P value
Physical 0.976 0.969–0.984 <0.001
Role 0.981 0.976–0.987 <0.001
Emotional 0.985 0.977–0.994 0.001
Cognitive 0.992 0.982–1.002 0.12
Social 0.985 0.978–0.991 <0.001
Fatigue 1.024 1.017–1.032 <0.001
Nausea/vomiting 1.019 1.011–1.028 <0.001
Pain 1.018 1.012–1.025 <0.001
Dyspnea 1.013 1.005–1.021 0.002
Insomnia 1.009 1.002–1.016 0.013
Appetite loss 1.022 1.016–1.028 <0.001
Constipation 1.022 1.015–1.028 <0.001
Diarrhea 1.008 0.998–1.018 0.12
Age at presentation 1.053 1.024–1.083 <0.001
Stage at diagnosis (locoregional disease as reference) 5.8 3.6–9.2 <0.001
Prior treatment history (analytic class as reference) 7.4 4.6–11.9 <0.001
Table 4 Univariate Cox regres-
sion analysis for overall
survival
Variable HR 95% CI P value
Physical 0.985 0.971–1.00 0.06
Role 1.004 0.990–1.018 0.62
Emotional 1.003 0.990–1.016 0.66
Social 1.005 0.994–1.017 0.36
Fatigue 1.017 1.001–1.034 0.03
Nausea/vomiting 0.994 0.981–1.008 0.39
Pain 0.997 0.986–1.008 0.62
Dyspnea 0.996 0.985–1.007 0.46
Insomnia 1.004 0.994–1.013 0.45
Appetite loss 1.008 0.998–1.019 0.12
Constipation 1.012 1.003–1.022 0.01
Age at presentation 1.033 1.005–1.062 0.02
Stage at diagnosis (locoregional disease as reference) 4.9 2.8–8.5 <0.001
Prior treatment history (analytic class as reference) 4.3 2.5–7.4 <0.001
Table 5 Multivariate Cox
regression analysis for overall
survival
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in this study, but this is acceptable for hypothesis-generating
studies [28]. We used a generic QoL questionnaire as
opposed to a prostate cancer-specific QoL tool. This is
because we have been collecting QoL information at our
center as part of our ongoing effort to systematically evaluate
and address patients' self-reported QoL. The current study is
a retrospective analysis of our routinely collected QoL data
on our prostate cancer patients. While patients' self-
assessment of their own health status provides a good and
strong indicator of their prognosis independent of previously
known traditional biomedical parameters, opinions vary as to
whether patient self-assessment of QoL is necessary or
physician assessment is adequate. There is skepticism about
the validity and utility of self-reported QoL measures.
Moreover, some clinicians are reluctant to use self-reported
QoL measures because they believe that they can obtain all
the pertinent information they will need during the clinical
assessment of the patient. Also self-assessment of QoL could
be challenging for patients who are unable to understand or
cooperate with study conditions.
Nevertheless, this study also has several strengths,
including complete data for all QLQ-C30 subscales for
the entire study sample, high compliance with completion
of the questionnaire, a reasonably homogeneous population
of patients, most of whom had stage II prostate cancer at
presentation to our hospitals, the use of a valid and reliable
QoL instrument, comprehensive documented clinical
parameters in nearly all patients, and availability of mature
and reliable survival data.
Conclusion
This study suggests that baseline QoL provides useful
prognostic information in prostate cancer patients sub-
jected to integrative oncologic care. In particular, fatigue
and constipation were independently predictive of sur-
vival. Given the greatly increased use of nutritional
supplements and other types of complementary treat-
ments practiced by prostate cancer patients following
their initial diagnosis, these findings illustrate the value
of QoL assessments for prognosis, clinical trial design,
best clinical practice validation, and optimization of
integrative models of care.
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